Navigation Links
EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
Date:9/8/2010

ROCKVILLE, Md., Sept. 8 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company focused on the development of ENMD-2076, its proprietary Aurora A/angiogenic kinase inhibitor for the treatment of cancer, today announced that on September 7, 2010 it entered into a securities purchase agreement with a group of strategic investors for gross proceeds of approximately $5.1 million.  The Company expects to complete the offering on or about September 8, 2010.  The financing will provide capital to fund operations through 2011 and enable the Company to move forward with expansion of development plans for ENMD-2076, which is currently in Phase 1 and Phase 2 clinical trials.  The ongoing Phase 2 trial of ENMD-2076 in ovarian cancer patients continues on track and the Company looks forward to the presentation of data early in 2011.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

The investor group was led by Tak W. Mak, Ph.D., Director of The Campbell Family Institute for Cancer Research, and includes scientific advisors to EntreMed as well as experienced investors who have expertise both in oncology drug development and in drug development in the China markets. Concurrent with the execution of the securities purchase agreement, EntreMed entered into a rights agreement with Selected Value Therapeutics I, LLC (SVT) pursuant to which SVT has an option to exercise, on behalf of the investors, certain license, development and commercialization rights for ENMD-2076 in China, enabling the Company to leverage the experience and access that these investors have in this growing market.  If the option is exercised, EntreMed will be entitled to receive development milestone payments and royalties on future product sales within the geographic market. Th
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
2. EntreMed Reports Second Quarter 2010 Financial Results
3. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
4. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
5. EntreMed Presents Initial Clinical Results for ENMD-2076
6. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
7. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
8. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
9. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
10. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
11. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 STAAR Surgical Company (NASDAQ: ... marketer of minimally invasive ophthalmic products, today announced that ... review the Company,s recent financial results and business developments ... will present at the 38 th Annual Deutsche ... at the Westin Waterfront Hotel on Wednesday, May ...
(Date:5/20/2013)... --   , Campaign launched ... to address the large physical and economic costs of ... affect 700 million people annually and account for 30 ... ,Do You Mind?, helps patients, family members, policymakers and ... collectively address MNDs , Today the International ...
(Date:5/20/2013)... Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Directors declared, at its meeting on May 16, 2013, ... for the third quarter of fiscal 2013.  The dividend ... of record on June 7, 2013. About ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Landauer, Inc. Declares Regular Cash Dividend 2
... TULSA, Okla., Sept. 1, 2011 Hillcrest ... SouthCrest Hospital in Tulsa, Okla., and Claremore Regional Hospital ... the agreement were not disclosed. The transaction ... Hospital, the 89-bed Claremore Regional Hospital, more than 70 ...
... PAUL, Minn., Sept. 1, 2011 Angeion Corporation (NASDAQ: ... third quarter ended July 31, 2011. Angeion ... the third quarter of fiscal 2010. Angeion incurred a net ... income of $126,000, or $0.03 per diluted share in the ...
Cached Medicine Technology:Hillcrest Completes Purchase of SouthCrest & Claremore Hospitals 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 3Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 4Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 5Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 6Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 7
(Date:5/21/2013)... of sudden infant death syndrome (SIDS) is five times ... study finds. British researchers noted that bed-sharing increases ... drink, use illegal drugs or smoke. They advised that ... infant death in developed countries, would drop dramatically if ... the United States, all parents are advised to not ...
(Date:5/21/2013)... The warning images Brussels proposes to include on tobacco ... the desired impact on smokers because they only find ... Commission wants to improve the efficacy of its anti-smoking ... that make a stronger emotional impact., These are some ... of Personality, Evaluation and Psychological Treatment at the University ...
(Date:5/21/2013)... known for their health benefits, and the subtropical ... drugs are delivered to specific tumor cells. , ... create nanoparticles using natural lipids derived from grapefruit, ... drug delivery vehicles. UofL scientists Huang-Ge Zhang, D.V.M., ... (May 21, 2013), published their findings in ...
(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that their re-launched bike ... achieved its overall goal of becoming a standalone brand. , ... Bicycles from a house brand to a standalone bike brand,” ... that the bike shop will go forward as Switchback ... 29er and 650b. , “The bike shop will ...
(Date:5/21/2013)... 21, 2013 TheBeautyPlace.com helps brides to ... features a Big Day Kit including all the essentials ... to shine on their Wedding Day. , TheBeautyPlace.com features ... about on their Wedding Day. Flowers blooming and warmer ... of wedding season. From Memorial Day to October, brides ...
Breaking Medicine News(10 mins):Health News:Bed-Sharing Raises SIDS Risk Fivefold, Study Finds 2Health News:Warning images for cigarette packs proposed by Europe do not make enough emotional impact 2Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3
... Itamar Medical ... ... Medicine, Mayo Clinic, Rochester, MN Dr. Peter Friberg, Sahlgrenska University ... Mr. Israel Schreiber, President and CEO, Itamar Medical ...
... reduced heart risks after angioplasty/stenting, but raised bleeding risks ... -- A new anti-clotting drug might one day challenge Plavix, ... procedures to open blocked coronary arteries, a new study suggests. ... -- notably those who had had a prior stroke, were ...
... ORLANDO, FL A North Carolina team of doctors, ... up with a way to provide faster, more effective ... require expensive drugs or fancy new equipment. But it ... on everyone involved to move treatment forward empowering ...
... Calif., Nov. 4 Consistent implementation of,proven ... to a Kaiser,Permanente (KP) abstract, published this ... in Orlando, Florida. The researchers followed ... to Kaiser Permanente emergency departments in Northern,California ...
... research suggests , , SUNDAY, Nov. 4 (HealthDay News) ... typically need open-heart surgery might someday have a new, ... , The balloon is inserted percutaneously (through the skin), ... said. In a new study, the procedure -- not ...
... risk of major cardiovascular events by 19, percent, significantly ... ... bleeding, TOKYO and INDIANAPOLIS, Nov. 4 ... investigational,antiplatelet agent prasugrel produced a highly significant 19 percent,reduction in relative ...
Cached Medicine News:Health News:How Early Can We Detect Cardiovascular Disease Less Expensively ... Even in Childhood? 2Health News:New Anti-Clotting Drug Shows Promise in Heart Patients 2Health News:New Anti-Clotting Drug Shows Promise in Heart Patients 3Health News:RACE: a statewide model of better, faster heart attack care 2Health News:RACE: a statewide model of better, faster heart attack care 3Health News:Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions 2Health News:Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions 3Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 2Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 3Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 2Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 3Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 4Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 5Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 6Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 7
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
50L...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: